Catalyst Health Economics Consultants

Haemophilia

1. Economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a minor bleed in haemophilia patients with high titre high responding inhibitors to coagulation Factors VIII and IX.

Presented at the American Society for Hematology Annual Meeting, San Francisco, December 2000.

View pdf

2. Economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the hospital treatment of a mild to moderate bleed among adult haemophilia patients with inhibitors in the UK.

Presented at The XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, July 2001.


3. Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK.

Authors: IAO Odeyemi & JF Guest.
Source: Journal of Medical Economics 2002; 5: 51-64.

View Abstract


4. Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK.

Authors: IAO Odeyemi & JF Guest.
Source: Journal of Medical Economics 2002; 5: 119-133.

View Abstract


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018